Volume surge · MRNA · Healthcare

Moderna Inc (MRNA) turnover jumps as four-week rebound reaches 36.4%

The biotechnology stock is back on the active-mover screen, but momentum evidence is not all one-way.

Moderna Inc
Latest63.96 USD
1W move28.2%
Volume1.7x
TrendActive
Moderna biotechnology lab setting with market data screen showing weekly stock chart context.

Market update

What happened

Moderna Inc (MRNA) closed the latest week at $63.96, extending a 28.2% one-week move and lifting its four-week return to 36.4%. The active-mover screen showed volume running about 2.3x its recent pace.

The 52-week weekly price path points to a sharp rebound rather than live intraday action. The trend signal is active, while Market Dynamics remains in weakness at -0.45 and Relative Strength is 42.9, leaving confirmation mixed.

Continue your research

Explore MRNA across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

MRNA coverage

Evidence context